Avantor (NYSE:AVTR) Price Target Cut to $25.00

Avantor (NYSE:AVTR) had its target price lowered by equities researchers at Barclays from $28.00 to $25.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 17.92% from the company’s current price.

Several other equities analysts have also weighed in on AVTR. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Avantor from $23.00 to $25.00 and gave the company a “hold” rating in a report on Thursday, April 18th. Evercore ISI boosted their price target on shares of Avantor from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, Robert W. Baird lowered their price target on shares of Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, April 29th. Four equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, Avantor presently has a consensus rating of “Moderate Buy” and a consensus target price of $26.36.

Avantor Trading Down 1.0 %

NYSE AVTR opened at $21.20 on Friday. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.94. Avantor has a 12 month low of $16.63 and a 12 month high of $26.16. The company’s 50-day moving average price is $23.73 and its 200-day moving average price is $23.81. The stock has a market cap of $14.40 billion, a PE ratio of 54.36, a PEG ratio of 2.17 and a beta of 1.35.

Avantor (NYSE:AVTR) last released its quarterly earnings results on Friday, April 26th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. The business had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.68 billion. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The company’s revenue was down 5.6% compared to the same quarter last year. During the same period last year, the business earned $0.29 EPS. Equities research analysts forecast that Avantor will post 1.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Mariner LLC increased its position in Avantor by 17.3% in the 3rd quarter. Mariner LLC now owns 42,025 shares of the company’s stock worth $886,000 after purchasing an additional 6,196 shares during the last quarter. Treasurer of the State of North Carolina lifted its position in shares of Avantor by 0.4% during the 3rd quarter. Treasurer of the State of North Carolina now owns 313,496 shares of the company’s stock worth $6,608,000 after buying an additional 1,187 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of Avantor by 170.4% during the 3rd quarter. Tower Research Capital LLC TRC now owns 24,722 shares of the company’s stock worth $521,000 after buying an additional 15,580 shares during the period. Bank of Nova Scotia lifted its position in shares of Avantor by 18.1% during the 3rd quarter. Bank of Nova Scotia now owns 16,024 shares of the company’s stock worth $338,000 after buying an additional 2,455 shares during the period. Finally, Fred Alger Management LLC acquired a new stake in Avantor during the 3rd quarter valued at $5,472,000. Institutional investors own 95.08% of the company’s stock.

About Avantor

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.